Colgate-Palmolive Company

Colgate-Palmolive raised its 2026 profit outlook after second-quarter earnings beat expectations and gross margin expanded 140 basis points. Base Business earnings were 99 cents per share, up 8% year over year and above the Zacks Consensus Estimate of 95 cents, while net sales rose 4.9% to $5.36 billion. Management now expects mid-single-digit Base Business EPS growth in 2026, up from its prior low- to mid-single-digit view, and improved its gross profit margin outlook to roughly flat year over year from down previously. Organic sales advanced 2.4%, with volume up 0.8% and pricing contributing 1.6%, though North America organic sales fell 3%. Advertising spending increased 15% to $777 million, and the company expects higher raw-material and tariff costs in the second half.

Colgate-Palmolive raised its quarterly dividend to $0.53 per share in 2026 from $0.52, bringing the annualized payout to $2.12 per share and extending its streak to 63 consecutive years of increases. The company reported second-quarter net sales up 4.9% to $5.36 billion, organic sales up 2.4%, and Base Business earnings per share up 8% to $0.99, while gross margin expanded 140 basis points to 61.5%. Operating cash flow for the first half of 2026 rose to $1.74 billion from $1.48 billion a year earlier, and free cash flow before dividends reached $1.48 billion, well above the $879 million paid in dividends. Management left its 2026 sales outlook unchanged but now expects mid-single-digit Base Business EPS growth, up from its previous low- to mid-single-digit expectation. The company holds a 41.3% global toothpaste market share and a 32.7% share of the manual toothbrush market year to date in 2026.

Spectrum Brands earned top marks in the second quarter household products earnings season. The company reported revenues of $753.3 million, up 7.7% year on year, exceeding analysts' expectations by 2.4%. WD-40 posted the biggest analyst estimate beat and fastest revenue growth in the group, with revenues of $195.1 million, up 24.3% year on year. Energizer reported revenues of $734.1 million, up 1.2% year on year, but missed analysts' EPS and EBITDA estimates. Central Garden & Pet had the slowest revenue growth, with revenues of $882.4 million, down 8.2% year on year. Colgate-Palmolive reported revenues of $5.36 billion, up 4.9% year on year, meeting analysts' expectations.

Colgate-Palmolive reported second-quarter 2026 earnings and sales that beat analyst expectations, driven by higher organic sales and strategic gains. Base Business earnings reached 99 cents per share, up 8% from a year ago and surpassing the Zacks Consensus Estimate of 95 cents. Net sales rose 4.9% to $5.36 billion, edging past the $5.35 billion consensus, with organic sales growth of 2.4% supported by a 0.8% volume increase and 1.6% pricing growth. Gross profit margin expanded 140 basis points to 61.5%, and the company raised its full-year Base Business earnings growth forecast to mid-single digits from low- to mid-single digits, while now expecting gross margin to be roughly flat rather than declining. Regional performance was mixed, with Latin America leading at 13.7% net sales growth, while North America sales fell 3%.

Colgate-Palmolive reported broad-based organic sales growth, gross margin expansion of 100 basis points, and an 18% increase in free cash flow in its second quarter of 2026, while outlining steps to improve performance in North America. Organic sales grew in four of the company's five divisions and in three of its four categories, led by emerging markets including India, Brazil, Mexico, and China, with Europe and the Hill's pet nutrition business also contributing. The company returned $1.4 billion to shareholders and increased advertising investment by double digits. Management now expects full-year gross margin to be roughly flat, an improvement from its prior expectation for a decline, though raw-material costs and tariffs are expected to be higher in the second half. In North America, softer category trends, retailer inventory reductions, and heightened competition weighed on results, and the company plans to increase brand support, expand premium innovation, and selectively address pricing and promotional gaps to drive second-half improvement.

X and the World Federation of Advertisers have settled litigation over an alleged advertiser boycott linked to the now-defunct Global Alliance for Responsible Media. The settlement follows a March ruling in which a U.S. judge dismissed X's antitrust lawsuit against the WFA and major companies including Mars, CVS Health, and Colgate-Palmolive. The WFA reaffirmed its commitment to freedom of speech and said it had permanently discontinued GARM in August 2024 and would not revive the initiative or create a similar program. The two organizations said brands, platforms, and consumers all stand to benefit from continued innovation in brand safety.

Four Dividend Kings are significantly outperforming the S&P 500's 9% gain in 2026 while offering reliable dividends backed by over 50 consecutive years of increases. Target surged 32% year to date and still trades at a cheap valuation with a 3.56% dividend yield. Colgate-Palmolive extended its 63-year dividend growth streak with a roughly 20.4% gain. Coca-Cola rose more than 16%, extending its 64-year dividend streak, and Kimberly-Clark advanced over 13% while yielding 4.41% and pursuing a $48.7 billion acquisition of Kenvue. All four stocks are rated Buy by top Wall Street firms.

Citi has released its stock picks and pans for the second half of 2026, covering real estate, technology and communications, consumer, and healthcare sectors. The bank's year-end S&P 500 target of 8100 is driven by the AI-capex super cycle, according to strategist Scott Chronert. In real estate, most preferred REITs include WELL, PLD, and CPT, while BDN is least preferred. In technology and communications, favored names span sub-sectors such as internet with AMZN, GOOGL, and DASH, and semiconductors with AMD, TXN, and AMAT, while least preferred include OPTU, UNIT, and CCOI in communications infrastructure and QRVO, SWKS, and OLED in semiconductors. Consumer sector top picks feature CL, PG, and KO in beverages, and MCD, CMG, and BROS in restaurants, with KMB and CBRL among the least preferred. In healthcare, most preferred stocks include LLY, VRTX, and GILD in biotech and large cap pharma, and EW, ISRG, and SYK in medical technology, while BAX and XRAY are among the least preferred.

Colgate-Palmolive has increased its dividend for the 64th consecutive year, extending a streak that began in 1895. The company recently raised its quarterly payout to $0.53 per share, supported by free cash flow of about $3.6 billion. In the first quarter of 2026, net sales rose 8.4%, exceeding analyst expectations, though earnings per share and gross profit margin declined due to inflationary pressures on materials. Colgate maintained its full-year 2026 guidance and continues to benefit from strong pricing power and global brand recognition. The stock has returned 16% year to date and offers a yield above 2%, with a forward P/E ratio of about 24.

Colgate-Palmolive has beaten earnings estimates in its last two quarters and may be poised for another beat when it reports next on July 31, 2026. The company topped estimates by an average of 3.25% over the past two quarters, most recently posting $0.97 per share against a $0.95 consensus. Analysts have been raising estimates, giving the stock a positive Earnings ESP of +0.78% and a Zacks Rank of 3, a combination that historically produces a positive surprise nearly 70% of the time.

Colgate-Palmolive is progressing with its 2030 plan, a multi-year transformation focused on premium product offerings and a tighter link between digital and physical retail. The strategy aims to reshape the company's business model in the consumer products sector, emphasizing higher-value goods and a connected shopping experience across online and in-store channels. Management highlights the plan as a way to align with changing consumer habits while remaining anchored in everyday staples. Investors are watching execution closely, particularly whether premiumization and omnichannel efforts can offset pressures from private-label competitors and cost inflation, while supporting the company's dividend track record and capital returns.

Among S&P 500 stocks, FactSet and MetLife are facing challenges while Colgate-Palmolive demonstrates competitive strengths. FactSet's annual sales growth of 5.8% and earnings per share growth of 5.9% over the last two years have underperformed the financial sector, and its stock trades at 12.1 times forward price-to-earnings. MetLife's net premiums earned grew just 2.7% annually over five years, earnings per share rose only 10.8% annually over two years, and book value per share declined 10.8% annually over five years amid credit quality concerns, with shares at 1.9 times forward price-to-book. In contrast, Colgate-Palmolive benefits from a $20.8 billion revenue base providing retail leverage, a 60.4% gross margin from premium pricing, and a 17.8% free cash flow margin enabling consistent reinvestment or capital returns, trading at 24.1 times forward price-to-earnings.

A bullish thesis on Colgate-Palmolive Company emphasizes its dividend growth, resilient cash generation, and long-term expansion potential through its pet nutrition segment. The company operates in over 200 countries with a diversified portfolio where oral, personal, and home care contribute 77% of sales and Hill's Pet Nutrition accounts for the remaining 23%. Management's 2030 strategic plan has delivered six consecutive years of organic sales growth and annual revenue exceeding $20 billion. As a Dividend King with 63 consecutive years of dividend increases, Colgate returns more than $1 billion annually through share repurchases. The pet nutrition business is expected to outpace traditional consumer staples, supported by rising pet humanization trends.

Colgate-Palmolive shares may be trading at an 8% discount to fair value, according to a widely followed narrative that points to a fair value of $96.68 against a recent close of $89.48. The consumer staples company has returned 15.18% year to date, though its one-year total shareholder return of 4.03% lags longer-term three- and five-year returns of 23.15% and 25.09%. The bullish case rests on productivity and restructuring initiatives worth $200 to $300 million over three years, which are expected to fund innovation, digital, and R&D investments and drive incremental margin expansion. However, the current price-to-earnings ratio of 34.3 times sits above an estimated fair ratio of 21.3 times and a peer average of 21.9 times, suggesting richer pricing and less room for error if growth or margins disappoint.

Colgate-Palmolive is effectively using its pricing power and innovation to support growth and offset cost pressures. The company's pricing strategy includes competitive pricing, value-based tactics, and price segmentation, while its productivity program focuses on cost savings and efficiency. Strong brand equity has enabled positive pricing momentum and resilient volume performance, particularly in emerging markets, despite a sluggish global consumption environment and inflationary pressures. Premium innovation launches such as Colgate Miracle Repair serum and EltaMD UV Skin Recovery are strengthening brand health and expanding household penetration. Colgate's shares have risen 16.6% over the past six months, and the stock currently carries a Zacks Rank #3 (Hold).